Amendment #164 to H4617

Rx Transparency

Ms. Barber of Somerville moves to amend the bill in Section 16, in line 270, by striking the words “financial, competitive or”;

and in Section 35, in line 682, by striking the word “and” and inserting in line 684 after the word “available”  the following:- “(iii) research and development costs as a percentage of revenue, costs paid with public funds, and costs paid by third parties, to the extent such costs are attributable to a specific product or set of products; (iv) annual marketing and advertising costs, identifying costs for direct-to-consumer advertising; and (v) cost disparities between prices charged to purchasers in the commonwealth and purchasers outside of the United States”

and in said section 35, in line 678, by striking the figure “25” and inserting in place thereof the figure “15”;

and in said section 35, by striking lines 685 through 689, inclusive;

and in said section 35, in line 700, by striking the words “financial, competitive or”.